Angle Plc Ord 10P is listed on the London Stock Exchange trading with ticker code AGL.L, and is part of the Support sector. It has a market capitalisation of £10,690m, with approximately 143m shares in issue. Over the last year, Angle Plc share price has been traded in a range of 40.5, hitting a high of 78.50, and a low of 38.00.
Angle Plc, officially known as Angle Plc Ord 10P was formed in December of 2003, making the company sixteen years old. The company filed its latest accounts on 30th April 2014, showing a turnover of approximately 801 thousand GBX, and a pre-tax profit margin of -154.56%. Angle Plc currently has 4 directors, and has had 5 previous directors over the last 16 years. In the last set of accounts produced by Baker Tilly Uk Audit Llp, the company showed 2.10 million paid in salaries to the 28 staff (average wage of 75 thousand), with the directors receiving an average 188 thousand each. In the accounts filed in 2014, the company paid 0 in dividends. These accounts also showed Angle Plc to have a net worth of 4.78 million, with 3.90 million held in cash.
|Metals Exploration Plc (MTL.L)|
|Trakm8 Holdings Plc (TRAK.L)|
|Begbies Traynor Group Plc (BEG.L)|
|Forbidden Technologies Plc (FBT.L)|
|Steppe Cement Ltd (STCM.L)|
|Shares in Issue||143m|
|52 Week High||78.50|
|52 Week Low||38.00|
ANGLE plc. Is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring. (Read more)